Grant Launches Starr Cancer Consortium

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 10
Volume 15
Issue 10

The Starr Foundation, one of the largest private foundations in the United States, has launched the multi-institutional Starr Cancer Consortium with a $100 million grant to coordinate the research efforts of five internationally recognized cancer research centers.

NEW YORK—The Starr Foundation, one of the largest private foundations in the United States, has launched the multi-institutional Starr Cancer Consortium with a $100 million grant to coordinate the research efforts of five internationally recognized cancer research centers. Consortium members include the Broad Institute of MIT and Harvard, Cold Spring Harbor Laboratory, Memorial Sloan-Kettering Cancer Center, The Rockefeller University, and Weill Cornell Medical College.

In addition to enabling collaboration on basic cancer research, the aim of the grant is to foster innovatative approaches to cancer prevention, diagnosis, and treatment, drawing on the strengths of the Consortium institutions. These include solid experience in investigations of translational genomics and animal and human cancer genetics, gold-standard clinical practice, and an extensive bank of cancer tissue specimens.

"Our goal in launching the Starr Cancer Consortium is to bring these exceptional institutions together in a manner that assures maximum efficiency and the greatest firepower in targeting cancer,"commented Starr Foundation chairman Maurice R. "Hank" Greenberg.

Key areas of focus for the new consortium will include:

• Creation or accelerated development of powerful technology platforms designed to unravel the genetic and molecular basis of cancers.

• Application of these technologies in joint projects aimed at developing new and highly effective approaches to diagnosis and treatment.

• Support for basic biological research to provide insights into the fundamental molecular and cellular processes underlying cancer.

The $100 million Starr Foundation grant will be targeted specifically to joint projects between two or more Consortium institutions, including several initiatives already in progress. In July, for example, The Tri-Institutional Stem Cell Initiative, comprising investigators from Memorial Sloan-Kettering Cancer Center, The Rockefeller University, and Weill Cornell Medical College, announced the first group of stem cell research projects to be funded through a $50 million gift from The Starr Foundation.

Projects selected for funding through the Consortium will be determined by an executive committee including Eric Lander, PhD, of the Broad Institute; Bruce Stillman, PhD, of Cold Spring Harbor Laboratory; Harold Varmus, MD, of Memorial Sloan-Kettering; Paul Nurse, PhD, of The Rockefeller University; and Antonio M. Gotto, Jr, MD, DPhil, of Weill Cornell Medical College. At a teleconference to announce the Consortium, Dr. Varmus said that Consortium institutions will hold a workshop next month to exchange ideas and identify potential projects for collaboration.

Recent Videos
9 Experts are featured in this series.
Vinay K. Puduvalli, MD, is featured in this series.
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
An advanced computation linguistics model that can detect pancreatic cysts can help patients prevent pancreatic tumors from forming.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
Related Content